Oromandibular dystonia as a complication of celebrotendinous xathomatosis

Movement Disorders

Volumn 24, Issue 9, 2009, Pages 1397-1399

  Alcalay, Roy N ^a   Wu, Stacy ^b   Patel, Shailendra ^c,d   Frucht, Steven ^a  

^a Columbia University ^*  (United States)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d CLEMENT J ZABLOCKI VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHENODEOXYCHOLIC ACID; CHOLESTANETRIOL 26 MONOOXYGENASE; CHOLESTANOL; DEXTROMETHORPHAN; QUINIDINE;

ADULT; ANAMNESIS; ARTICLE; ATAXIA; BABINSKI REFLEX; CASE REPORT; CATARACT; CEREBROTENDINOUS XANTHOMATOSIS; DEHYDRATION; DYSMETRIA; DYSTONIA; FALLING; FEMALE; FOOT MALFORMATION; GENE MUTATION; HUMAN; LEARNING DISORDER; OROMANDIBULAR DYSTONIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSEUDOBULBAR PALSY; VIBRATION DISEASE;

ADULT; CATHARTICS; CEREBELLUM; CHENODEOXYCHOLIC ACID; CYTOCHROME P-450 CYP27A1; DYSTONIA; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MUTATION; XANTHOMATOSIS, CEREBROTENDINOUS;

EID: 69549085104     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22585     Document Type: Article

References (12)

1. Verrips A, Hoefsloot LH, Steenbergen GC, et al. Clinical and molecular genetic characteristics of patients with cerebrotendinous xanthomatosis. Brain 2000;123 (Part 5):908-919.
2. Berginer VM, Salen G, Shefer S. Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid. N Engl J Med 1984;311:1649-1652.
3. Okuma H, Kitagawa Y, Tokuoka K, Takagi S. Cerebrotendinous xanthomatosis with cerebellar ataxia as the chief symptom. Intern Med 2007;46:1259-1261.
4. Leitersdorf E, Reshef A, Meiner V, et al. Frameshift and splice-junction mutations in the sterol 27-hydroxylase gene cause cerebrotendinous xanthomatosis in Jews or Moroccan origin. J Clin Invest 1993;91:2488-2496.
5. Lee MH, Hazard S, Carpten JD, et al. Fine-mapping, mutation analyses, and structural mapping of cerebrotendinous xanthomatosis in U.S. pedigrees. J Lipid Res 2001;42:159-169.
6. Brooks BR, Thisted RA, Appel SH, et al. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology 2004;63:1364-1370.
7. Bordia S, Saifee AA. Cerebrotendinous xanthomatosis with oromandibular dyskinesia. Neurol India 2003;51:556-558.
8. Szlago M, Gallus GN, Schenone A, et al. The first cerebrotendinous xanthomatosis family from Argentina: a new mutation in CYP27A1 gene. Neurology 2008;70:402-404.
9. Pilo de la Fuente B, Ruiz I, Lopez de Munain A, Jimenez-Escrig A. Cerebrotendinous xanthomatosis: neuropathological findings. J Neurol 2008;255:839-842.
10. Geyer HL, Bressman SB. The diagnosis of dystonia. Lancet Neurol 2006;5:780-790.
11. Kuriyama M, Tokimura Y, Fujiyama J, Utatsu Y, Osame M. Treatment of cerebrotendinous xanthomatosis: effects of chenodeoxycholic acid, pravastatin, and combined use. J Neurol Sci 1994;125:22-28.
12. Verrips A, Wevers RA, Van Engelen BG, et al. Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis. Metabolism 1999;48:233-238.